Tyme (TYME) 10-Q 8 Aug 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2019	Aug. 02, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	0001537917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		111,950,937
Entity Address, Address Line One	17 State Street – 7th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	New York
Entity Address, Postal Zip Code	10004
City Area Code	212
Local Phone Number	461-2315
Entity Shell Company	false
Entity File Number	001-38169
Entity Tax Identification Number	453864597
Entity Current Reporting Status	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Current Assets
Cash and cash equivalents	$ 19,466,419	$ 14,302,328
Prepaid rent		242,755
Prepaid clinical costs	447,308	592,134
Prepaid expenses and other current assets	556,513	1,001,898
Total current assets	20,470,240	16,139,115
Property and equipment, net	9,067	10,363
Prepaid rent, net of current portion		101,148
Prepaid clinical costs, net of current portion	1,266,025	1,266,025
Operating lease right-of-use asset	374,347
Total assets	22,119,679	17,516,651
Current liabilities
Accounts payable and other current liabilities (including $377,000 and $325,000 of related party accounts payable, respectively)	3,163,539	3,692,308
Severance payable	364,112	428,240
Accrued bonuses	424,423	1,495,248
Insurance note payable	195,344	597,339
Operating lease liability	55,141
Total current liabilities	4,202,559	6,213,135
Long-term liabilities
Severance payable	1,543,731	1,635,634
Operating lease liability, net of current portion	42,001
Warrant liability	4,345,359
Total liabilities	10,133,650	7,848,769
Commitments and contingencies (see Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 111,950,937 issued and outstanding at June 30, 2019, 300,000,000 authorized, 103,946,048 issued and outstanding at March 31, 2019	11,197	10,397
Additional paid in capital	100,981,514	95,472,181
Accumulated deficit	(89,006,682)	(85,814,696)
Total stockholders' equity	11,986,029	9,667,882
Total liabilities and stockholders' equity	$ 22,119,679	$ 17,516,651

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	111,950,937	103,946,048
Common stock, outstanding	111,950,937	103,946,048
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 377,000	$ 325,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating expenses:
Research and development	2,720,762	3,010,688
General and administrative (including $152,000 and $400,000 of related party legal expenses, respectively)	3,456,724	3,708,481
Total operating expenses	6,177,486	6,719,169
Loss from operations	(6,177,486)	(6,719,169)
Other income (expenses):
Change in fair value of warrant liability	2,938,242
Interest income	80,237
Interest expense	(32,979)	(3,627)
Total other income (expenses)	2,985,500	(3,627)
Net loss	$ (3,191,986)	$ (6,722,796)
Basic and diluted loss per common share	$ (0.03)	$ (0.07)
Basic and diluted weighted average shares outstanding	111,862,541	101,226,479

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Related party legal expenses	$ 152,000	$ 400,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in capital [Member]	Accumulated Deficit [Member]
Balance, at beginning at Mar. 31, 2018	$ 26,471,967	$ 10,125	$ 79,293,423	$ (52,831,581)
Balance, at beginning (in shares) at Mar. 31, 2018		101,226,479
Stock based compensation	2,338,408		2,338,408
Net loss	(6,722,796)			(6,722,796)
Balance, at end at Jun. 30, 2018	22,087,579	$ 10,125	81,631,831	(59,554,377)
Balance, at end (in shares) at Jun. 30, 2018		101,226,479
Balance, at beginning at Mar. 31, 2018	26,471,967	$ 10,125	79,293,423	(52,831,581)
Balance, at beginning (in shares) at Mar. 31, 2018		101,226,479
Balance, at end at Mar. 31, 2019	$ 9,667,882	$ 10,397	95,472,181	(85,814,696)
Balance, at end (in shares) at Mar. 31, 2019	103,946,048	103,946,048
Issuance of common stock from underwritten registered offering, net of associated expenses of $111,227	$ 3,885,172	$ 800	3,884,372
Issuance of common stock from underwritten registered offering, net of associated expenses (in shares)		8,000,000
Cashless exercise of warrants (in shares)		4,889
Stock based compensation	1,624,961		1,624,961
Net loss	(3,191,986)			(3,191,986)
Balance, at end at Jun. 30, 2019	$ 11,986,029	$ 11,197	$ 100,981,514	$ (89,006,682)
Balance, at end (in shares) at Jun. 30, 2019	111,950,937	111,950,937

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)	3 Months Ended
	Jun. 30, 2019USD ($)
Underwritten Registered Offering [Member]
Offering expense	$ 111,227

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (3,191,986)	$ (6,722,796)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	1,296	2,369
Amortization of employees, directors and consultants stock options	1,624,961	2,338,408
Change in fair value of warrant liability	(2,938,242)
Change in operating assets and liabilities:
Prepaid rent		(525,969)
Prepaid clinical costs	144,826
Prepaid expenses and other assets	445,385	(54,818)
Operating lease right-of-use asset	73,550
Accounts payable and other current liabilities	(528,769)	(99,417)
Severance payable	(156,031)
Accrued bonuses	(1,070,825)	(1,248,690)
Operating lease liability	(6,852)
Net cash provided by (used in) operating expenses	(5,602,687)	(6,310,913)
Cash flows from investing activities
Purchase of property & equipment		(15,543)
Net cash used in investing activities		(15,543)
Cash flows from financing activities
Insurance note payments	(401,995)	(210,769)
Proceeds from underwritten registered offering, net of issuance costs	11,168,773
Net cash provided by (used in) financing activities	10,766,778	(210,769)
Net increase (decrease) in cash and cash equivalents	5,164,091	(6,537,225)
Cash and cash equivalents - beginning	14,302,328	28,975,822
Cash and cash equivalents - ending	19,466,419	22,438,597
Supplemental Cash Flow Information:
Interest	$ 32,979	$ 3,627

Nature of Business

Nature of Business	3 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in New York, NY, with wholly-owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (“Luminant”) (collectively, “TYME” or the “Company”). Prior to 2014, Luminant conducted the initial research and development of the Company’s therapeutic platform. Since January 1, 2014, the majority of the Company’s research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM The Company’s lead clinical CMBT program, SM-88 (racemetyrosine), is a novel, oral, monotherapy investigational agent that has been studied in clinical trials for over five years in approximately 180 cancer patients. TYME recently completed enrollment for two Phase II clinical trials in prostate and pancreatic cancer, and the Company is preparing for pivotal studies for SM-88 in pancreatic cancer during the second half of calendar year 2019. One of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing TYME-88-Panc trial (Part 2). The Company has also partnered with the Pancreatic Cancer Action Network (“PanCAN”) to study SM-88 in an adaptive pivotal trial known as Precision Promise SM The accompanying condensed consolidated financial statements include the results of operations of Tyme Technologies, Inc. and its wholly-owned subsidiaries. Liquidity The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. During the three months ended June 30, 2019, the Company raised net proceeds of approximately $11.3 million after underwriting discounts and before expenses through an underwritten registered offering. Previously on November 2, 2017, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Canaccord Genuity Inc. (“Canaccord”), to commence an at-the-market offering (the “ATM Financing Facility”) pursuant to which the Company may, from time to time, sell shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price up to $30.0 million, through Canaccord, as the Company’s sales agent. In the year ended March 31, 2019, the Company raised approximately $5.8 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.2 million. The Company did not sell any shares through the ATM Financing Facility during the three months ended June 30 2019 and at June 30, 2019, there remained approximately $17.9 million of availability to sell shares through the ATM Financing Facility. The proceeds of those offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the three months ended June 30, 2019, the Company had negative cash flow from operations of $5.6 million and net loss of $3.2 million, which included non-cash income of $2.9 million (related to change in fair value of warrant liability) and $1.6 million of non-cash expenses, primarily non-cash equity compensation expense. As of June 30, 2019, the Company had working capital of approximately $16.3 million. Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements . This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended March 31, 2019 filed with the Securities and Exchange Commission (the “SEC”) on June 12, 2019 (the “2019 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiaries, Tyme Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2019 included in the Company’s 2019 10-K. Reclassifications The Company has reclassified certain prior period amounts to conform to the current period presentation relating to severance payable of $95,021. These reclassifications have no effect on the previously reported net loss or cash flows. Fair Value of Financial Instruments The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the derivative liability is discussed in Note 6. Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features which cause the warrants to be treated as derivatives. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. Recent Accounting Pronouncements The Company adopted ASU 2016‑02, Leases (Topic 842) Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred. The Company elected the optional practical expedients to forgo applying guidance in Topic 842 to short-term leases (leases 12 or fewer months at commencement and no purchase option). The package of expedients allows an entity to forgo reassessing (1) whether a contract contains a lease, (2) classification of leases, and (3) whether capitalized costs associated with a lease meet the definition of “initial direct costs” in Topic 842. The Company elected to use the optional transition method and therefore prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC 840, Leases (Topic 840) Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its condensed consolidated balance sheet of approximately $0.4 million and $0.1 million, respectively. The Company also classified prepaid rent of $0.3 million as an operating right-of-use asset upon adoption. There were no adjustments to the Company’s opening accumulated deficit upon adoption. The impact of the adoption of Topic 842 on the condensed consolidated balance sheets as of April 1, 2019 is as follows: April 1, 2019 April 1, 2019 Prior to of ASC 842 ASC 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994 In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended June 30, 2019 2018 Basic and diluted net loss per common share calculation: Net loss $ (3,191,986 ) $ (6,722,796 ) Weighted average common shares outstanding — basic and diluted: 111,862,541 101,226,479 Net loss per share of common stock — basic and diluted $ (0.03 ) $ (0.07 ) The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company common stock outstanding for the period, and diluted earnings per share is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive. Warrants issued in April 2019 participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors on the Corporation’s common stock. For purposes of computing EPS, these warrants are considered to participate with common stock in the earnings of the Company and, therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed earnings. No income was allocated to the Warrants for the three months ended June 30, 2019 as results of operations was a loss for the period. The following outstanding securities at June 30, 2019 and 2018 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: June 30 , 2019 2018 Stock options 11,460,807 7,305,472 Warrants 12,421,172 5,615,641 Total 23,881,979 12,921,113

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	3 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 4. Accounts Payable and Other Current Liabilities Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: June 30, 2019 March 31, 2019 Legal $ 808,941 $ 602,129 Consultant and professional services 122,089 170,257 Accounting and auditing 255,971 331,119 Research and development 1,243,031 1,907,787 Board of Directors and Scientific Advisory Board Compensation 479,343 489,393 Other 254,164 191,623 Total $ 3,163,539 $ 3,692,308

Severance Payable

Severance Payable	3 Months Ended
	Jun. 30, 2019
Severance Payable [Abstract]
Severance Payable	Note 5. Severance Payable On March 15, 2019 the Company entered into a Release Agreement related to the separation of employment of its then-Chief Operating Officer. The agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The severance liability payable as of June 30, 2019 and March 31, 2019 was $1.9 million and $2.1 million, respectively.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 6. Fair Value Measurements The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the derivative liability is discussed below. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below. Level 1 : Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. Level 3 : Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis. The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Other than the warrants issued in connection with the issuance of common stock from underwritten registered offering which closed on April 2, 2019, the Company had no assets or liabilities classified as Level 3 as of March 31, 2019 or June 30, 2019. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the three months ended June 30, 2019. The fair value of the warrants is considered a Level 3 valuation and was determined using a Monte Carlo simulation model. This model incorporated several assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, its expected volatility, the remaining contractual term of the warrant, the risk free interest rate over the term and estimates of the probability of fundamental transactions occurring (See Note 8 for further discussion of the issuance of common stock from underwritten registered offering). The Company’s financial instruments measured at fair value on a recurring basis are as follows: Description Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) (in thousands) June 30, 2019 Warrant liability $ 4,345 — — $ 4,345 March 31, 2019 Warrant liability — — — — The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: June 30, 2019 (in thousands) Beginning balance, March 31, 2019 $ - Fair value of liability-classified warrants issued with common stock 7,283 Change in fair value of warrant liability (2,938 ) Ending balance $ 4,345

Debt

Debt	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt	Note 7. Debt Insurance Note Payable During the year ended March 31, 2019, the Company entered into a short-term financing arrangement with its insurance carrier related to payment of premium for its Director and Officer liability insurance coverage totaling $0.6 million for the policy year ending on March 18, 2020. As of June 30, 2019 and March 31, 2019, there remained a balance of $0.2 million and $0.6 million, respectively, recorded to Insurance note payable on the accompanying consolidated balance sheets.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity At each of June 30, 2019 and March 31, 2019, 12,391,405 and 4,469,836, respectively, of common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. The following summarizes the common stock warrant activity for the three months ended June 30, 2019: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2019 4,499,603 $ 3.42 Granted 8,000,000 2.00 Exercised (78,431 ) 3.00 Outstanding at June 30, 2019 12,421,172 $ 2.51 At-the-Market Financing Facility On November 2, 2017, the Company entered into the Equity Distribution Agreement with Canaccord, to commence the ATM Financing Facility. For the three months ended June 30, 2019, the Company did not sell shares under ATM Financing Facility. At June 30, 2019 and March 31, 2019, there remained approximately $17.9 million of availability to sell shares through the facility. In the year ended March 31, 2019, the Company raised approximately $5.8 million in gross proceeds through the ATM via sale of 2,383,884 shares of our common stock. The Company incurred $0.2 million of related costs which offset the proceeds. Under the ATM Financing Facility, the Company is not required to issue the full available amount authorized and it may be cancelled at any time. Warrants The Company has warrants to purchase its common stock outstanding as of June 30, 2019, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 491,151 5.00 February 2026 March 2017 Equity 3,245,288 3.00 September 2019 April 2017 Equity 238,233 3.00 September 2019 April 2019 Liability 8,000,000 2.00 April 2024 April 2019 - Registered Offering In April 2019, the Company completed an underwritten registered offering, (the “Offering”) of 8,000,000 shares of common stock at a price of $1.50 per share. The total net proceeds of the offering were $11.3 million after deducting underwriter’s discounts and before expenses related to the offering. As part of the Offering, the investors received warrants to purchase up to 8,000,000 shares of the Company’s common stock at an exercise price of $2.00 per share (the “Warrants”). The Warrants participate with common stock on a one-for-one basis for distribution dividends or other assets of the Company. The exercise price of the Warrants is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s common stock. Subject to certain exceptions, if the Company issues or sells common stock or other securities convertible into common stock during the term of the Warrants at a per share price less than the exercise price of the Warrants, or if the Company subsequently reduces the exercise price of equity-linked instruments that were outstanding on April 2, 2019, the exercise price of the Warrants will be reduced to such lower sale or exercise price. The Company determined that the Warrants should be recorded as a derivative liability on the condensed consolidated balance sheet due to the Warrants’ contractual provisions requiring issuance of registered common shares upon exercise and certain price protection rights. At the issuance date, the Warrants were recorded at the fair value of $7.3 million as determined using the Monte Carlo pricing simulation. The Warrants were re-measured at June 30, 2019 and the change in fair value of $2.9 million was recorded as a component of other income (expense) within the condensed consolidated statement of operations. The following table details key inputs and assumptions used in the Monte Carlo simulation models used to estimate the fair value of the Warrant Liability as of June 30, 2019 and April 2, 2019, respectively: June 30, 2019 April 2, 2019 Stock price $ 1.22 $ 1.85 Volatility 56 % 48 % Remaining term (years) 4.76 5.00 Expected dividend yield — — Risk-free rate 1.75 % 2.28 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. On June 30, 2019, the Company amended the Clinical Research Funding and Drug Supply Agreement dated October 9, 2018, with Pancreatic Cancer Action Network (“PanCAN”), to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study is expected to start in the second half of calendar year 2019. After taking into consideration amounts already paid, the remaining estimated cost to the Company is approximately $7.0 million, subject to enrollment adjustments. Purchase Commitments The Company has entered into three contracts with manufacturers to supply certain components used in SM- 88 in order to achieve favorable pricing on supplied products. These contracts have non-cancellable elements related to the scheduled deliveries of these products in future periods. Payments are made by us to the manufacturer when the products are delivered and of acceptable quality. The contracts are structured to match clinical supply needs for our ongoing trials and we expect the timing of associated payments to predominately occur during fiscal year 2020. Total outstanding future obligations associated with the contracts were $2.5 million at June 30, 2019. Legal Proceedings From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred. The Company is not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on us, our business, operating results or financial condition.

Leases

Leases	3 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	Note 10. Leases The Company leases office space in New York and office space and furniture in New Jersey. The New York rent obligation has been prepaid through August 30, 2020, the end of the lease. The New Jersey leases expire in February 2021. Total company rent expense for the three months ended June 30, 2019 and 2018, including short term rentals was approximately $76,000 and $43,000, respectively. Operating lease right-of-use (“ROU”) assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms . ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets As of June 30, 2019, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease right-of-use assets and lease liabilities were as follows: Quarter ended June 30, 2019 Remainder of 2020 $ 44,000 2021 58,000 2022 — Total remaining lease payments 102,000 Less: present value adjustment (5,000 ) Total operating lease liabilities 97,000 Less: current portion (55,000 ) Operating lease liabilities, net of current portion $ 42,000

Related Party Transactions

Related Party Transactions	3 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Legal Drinker Biddle & Reath LLP (“DBR”) has provided legal services to the Company. A partner of DBR was a member of the Board of Directors and had received, and was entitled to receive in the future, cash compensation payable to non-employee directors generally and equity compensation payable to non-employee directors under the 2016 Director Plan. See Note 10, Equity Incentive Plan. On September 10, 2018, the Company entered into an employment agreement with the partner and he was appointed as the Company’s Chief Legal Officer and Secretary. He ceased to be a non-employee director on September 10, 2018 and he resigned as a member of the Board, effective September 30, 2018. On September 1, 2018, the partner resigned from the partnership of DBR and he assumed the consulting role “of Counsel” with the firm. During the three months ending June 30, 2019 and 2018, approximately $152,000, and $400,000, respectively, have been incurred as legal fees associated with DBR. At June 30, 2019 and March 31, 2019, the Company had approximately $377,000 and $325,000, respectively, in accounts payable and accrued expenses payable to DBR.

Equity Incentive Plan

Equity Incentive Plan	3 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 12. Equity Incentive Plan Stock Options As of June 30, 2019, there was approximately $8.3 million of total unrecognized compensation expense related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average service period of 1.09 Stock based compensation expense recognized was as follows: Three Months Ended June 30, 2019 2018 General and administrative $ 955,000 $ 1,661,000 Research and development 670,000 677,000 Total $ 1,625,000 $ 2,338,000 The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, the compensation expense is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees, non-employees and consultants in the current fiscal period has been based on the term by using the simplified method as allowed under SAB No. 110 and ASU 2018-7. The weighted average assumptions used to determine such values are presented in the following table: June 30, 2019 June 30, 2018 Risk free interest rate 1.91% - 2.38% 2.87 % Expected volatility 71.65% - 76.22% 75.09 % Expected term (in years) 2.5 - 6 5.91 Dividend yield 0 % 0 % The following is a summary of the status of the Company’s stock options as of June 30, 2019: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2019 8,953,527 $ 4.13 Granted 2,507,280 1.55 Outstanding at June 30, 2019 11,460,807 3.57 Options exercisable at June 30, 2019 6,095,259 4.65 Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at June 30, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at June 30, 2019 Weighted Average Exercise Price Aggregate Intrinsic Value $1.04 - $8.75 11,460,807 $ 3.57 8.11 $ - 6,095,259 $ 4.65 $ - The intrinsic value calculated as the excess of the market value as of June 30, 2019 over the exercise price of the options, is zero. The market value per share as of June 30, 2019 was $1.22 as reported by the NASDAQ Capital Market.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company weighed available positive and negative evidence and concluded that a full valuation allowance should continue to be maintained on its net deferred tax assets. The Company is required to evaluate uncertain tax positions taken or expected to be taken in the course of preparing the Company’s condensed consolidated financial statements to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. As of June 30, 2019, the Company’s uncertain tax positions remain unchanged. Due to the full valuation allowance, none of the gross unrecognized tax benefits would affect the effective tax rate at June 30, 2019, if recognized. The Company had no income tax related penalties or interest for periods presented in these condensed consolidated financial statements related to uncertain tax positions due to available net operating loss carryforwards, which would be recorded as tax expense should the Company accrue for such items.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended March 31, 2019 filed with the Securities and Exchange Commission (the “SEC”) on June 12, 2019 (the “2019 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiaries, Tyme Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2019 included in the Company’s 2019 10-K.
Reclassifications	Reclassifications The Company has reclassified certain prior period amounts to conform to the current period presentation relating to severance payable of $95,021. These reclassifications have no effect on the previously reported net loss or cash flows.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the derivative liability is discussed in Note 6.
Derivative Warrant Liability	Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features which cause the warrants to be treated as derivatives. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company adopted ASU 2016‑02, Leases (Topic 842) Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred. The Company elected the optional practical expedients to forgo applying guidance in Topic 842 to short-term leases (leases 12 or fewer months at commencement and no purchase option). The package of expedients allows an entity to forgo reassessing (1) whether a contract contains a lease, (2) classification of leases, and (3) whether capitalized costs associated with a lease meet the definition of “initial direct costs” in Topic 842. The Company elected to use the optional transition method and therefore prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC 840, Leases (Topic 840) Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its condensed consolidated balance sheet of approximately $0.4 million and $0.1 million, respectively. The Company also classified prepaid rent of $0.3 million as an operating right-of-use asset upon adoption. There were no adjustments to the Company’s opening accumulated deficit upon adoption. The impact of the adoption of Topic 842 on the condensed consolidated balance sheets as of April 1, 2019 is as follows: April 1, 2019 April 1, 2019 Prior to of ASC 842 ASC 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994 In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Impact of Adoption of Topic 842 on Condensed Consolidated Balance Sheets	The impact of the adoption of Topic 842 on the condensed consolidated balance sheets as of April 1, 2019 is as follows: April 1, 2019 April 1, 2019 Prior to of ASC 842 ASC 842 Adjustment As Adjusted Prepaid rent $ 343,903 $ (343,903 ) $ — Deferred rent $ — $ — $ — Operating right-of-use assets $ — $ 447,897 $ 447,897 Operating lease liability $ — $ 103,994 $ 103,994

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended June 30, 2019 2018 Basic and diluted net loss per common share calculation: Net loss $ (3,191,986 ) $ (6,722,796 ) Weighted average common shares outstanding — basic and diluted: 111,862,541 101,226,479 Net loss per share of common stock — basic and diluted $ (0.03 ) $ (0.07 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at June 30, 2019 and 2018 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: June 30 , 2019 2018 Stock options 11,460,807 7,305,472 Warrants 12,421,172 5,615,641 Total 23,881,979 12,921,113

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	3 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: June 30, 2019 March 31, 2019 Legal $ 808,941 $ 602,129 Consultant and professional services 122,089 170,257 Accounting and auditing 255,971 331,119 Research and development 1,243,031 1,907,787 Board of Directors and Scientific Advisory Board Compensation 479,343 489,393 Other 254,164 191,623 Total $ 3,163,539 $ 3,692,308

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The Company’s financial instruments measured at fair value on a recurring basis are as follows: Description Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) (in thousands) June 30, 2019 Warrant liability $ 4,345 — — $ 4,345 March 31, 2019 Warrant liability — — — —
Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs	The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: June 30, 2019 (in thousands) Beginning balance, March 31, 2019 $ - Fair value of liability-classified warrants issued with common stock 7,283 Change in fair value of warrant liability (2,938 ) Ending balance $ 4,345

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the three months ended June 30, 2019: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2019 4,499,603 $ 3.42 Granted 8,000,000 2.00 Exercised (78,431 ) 3.00 Outstanding at June 30, 2019 12,421,172 $ 2.51
Schedule of Warrants to Purchase Common Stock Outstanding	The Company has warrants to purchase its common stock outstanding as of June 30, 2019, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 491,151 5.00 February 2026 March 2017 Equity 3,245,288 3.00 September 2019 April 2017 Equity 238,233 3.00 September 2019 April 2019 Liability 8,000,000 2.00 April 2024
Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant Liability	The following table details key inputs and assumptions used in the Monte Carlo simulation models used to estimate the fair value of the Warrant Liability as of June 30, 2019 and April 2, 2019, respectively: June 30, 2019 April 2, 2019 Stock price $ 1.22 $ 1.85 Volatility 56 % 48 % Remaining term (years) 4.76 5.00 Expected dividend yield — — Risk-free rate 1.75 % 2.28 %

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements	As of June 30, 2019, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease right-of-use assets and lease liabilities were as follows: Quarter ended June 30, 2019 Remainder of 2020 $ 44,000 2021 58,000 2022 — Total remaining lease payments 102,000 Less: present value adjustment (5,000 ) Total operating lease liabilities 97,000 Less: current portion (55,000 ) Operating lease liabilities, net of current portion $ 42,000

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	3 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock based compensation expense	Stock based compensation expense recognized was as follows: Three Months Ended June 30, 2019 2018 General and administrative $ 955,000 $ 1,661,000 Research and development 670,000 677,000 Total $ 1,625,000 $ 2,338,000
Schedule of Assumptions Used to Estimate the Fair Value of Stock Options Granted	The weighted average assumptions used to determine such values are presented in the following table: June 30, 2019 June 30, 2018 Risk free interest rate 1.91% - 2.38% 2.87 % Expected volatility 71.65% - 76.22% 75.09 % Expected term (in years) 2.5 - 6 5.91 Dividend yield 0 % 0 %
Schedule of Stock Options	The following is a summary of the status of the Company’s stock options as of June 30, 2019: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2019 8,953,527 $ 4.13 Granted 2,507,280 1.55 Outstanding at June 30, 2019 11,460,807 3.57 Options exercisable at June 30, 2019 6,095,259 4.65
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at June 30, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at June 30, 2019 Weighted Average Exercise Price Aggregate Intrinsic Value $1.04 - $8.75 11,460,807 $ 3.57 8.11 $ - 6,095,259 $ 4.65 $ -

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Nov. 02, 2017
Nature Of Business [Line Items]
Common stock, par value		$ 0.0001		$ 0.0001
Available for offering		$ 17,900,000		$ 17,900,000
Number of shares issued upon new issue	8,000,000
Net cash used in operating activities		(5,602,687)	$ (6,310,913)
Net loss		(3,191,986)	$ (6,722,796)
Non-cash expense		1,600,000
Working capital		16,300,000
Non-cash income		2,900,000
Maximum [Member]
Nature Of Business [Line Items]
Aggregate offering					$ 30,000,000
Underwriters Public Offering [Member]
Nature Of Business [Line Items]
Cash proceeds from private placement	$ 11,300,000	11,300,000
Offering expense		$ 111,227
ATM Financing Facility [Member]
Nature Of Business [Line Items]
Gross proceeds from issuance of common stock				5,800,000
Offering expense				$ 200,000
Number of shares issued upon new issue		0		2,383,884

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2019	Apr. 01, 2019
Significant Accounting Policies [Line Items]
Operating right-of-use assets	$ 374,347	$ 447,897
Operating lease liability	97,000	103,994
Topic 842 [Member]
Significant Accounting Policies [Line Items]
Adjustment to opening accumulated deficit		0
Operating Right-of-Use Asset [Member] | Topic 842 [Member]
Significant Accounting Policies [Line Items]
Classified prepaid rent as operating right-of-use asset		$ 300,000
Severance Payable [Member]
Significant Accounting Policies [Line Items]
Reclassified prior period amounts relating to severance payable	$ 95,021

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of Topic 842 on Condensed Consolidated Balance Sheets (Detail) - USD ($)	Jun. 30, 2019	Apr. 01, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating right-of-use assets	$ 374,347	$ 447,897
Operating lease liability	$ 97,000	103,994
Prior to Adoption of ASC 842 [Member] | Topic 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Prepaid rent		343,903
Adjustment [Member] | Topic 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Prepaid rent		(343,903)
Operating right-of-use assets		447,897
Operating lease liability		$ 103,994

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Basic and diluted net loss per common share calculation:
Net loss	$ (3,191,986)	$ (6,722,796)
Weighted average common shares outstanding — basic and diluted:	111,862,541	101,226,479
Net loss per share of common stock — basic and diluted	$ (0.03)	$ (0.07)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2019USD ($)	Apr. 30, 2019
Earnings Per Share [Abstract]
Description of warrants issued	Warrants issued in April 2019 participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors on the Corporation’s common stock
Warrants issued for common stock dividends		1
Income allocated to warrants	$ 0

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	23,881,979	12,921,113
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	11,460,807	7,305,472
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	12,421,172	5,615,641

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Payables And Accruals [Abstract]
Legal	$ 808,941	$ 602,129
Consultant and professional services	122,089	170,257
Accounting and auditing	255,971	331,119
Research and development	1,243,031	1,907,787
Board of Directors and Scientific Advisory Board Compensation	479,343	489,393
Other	254,164	191,623
Total	$ 3,163,539	$ 3,692,308

Severance Payable - Additional

Severance Payable - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Severance Payable [Line Items]
Salary continuance term	5 years
Reimbursement of health benefits term	3 years
Severance expense		$ 2.5
Discount rate		6.00%
Stock option modification expense		$ 0.4
Severance liability	$ 1.9	$ 2.1
Minimum [Member]
Severance Payable [Line Items]
Post-termination exercise period	3 months
Maximum [Member]
Severance Payable [Line Items]
Post-termination exercise period	5 years

Fair Value of Financial Instrum

Fair Value of Financial Instruments - Additional Information (Detail) - Fair Value, Measurements, Recurring [Member] - Level 3 [Member] - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0	$ 0
Liabilities measured at fair value	$ 0	$ 0

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] $ in Thousands	Jun. 30, 2019USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$ 4,345
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$ 4,345

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs (Detail) - Level 3 [Member] $ in Thousands	3 Months Ended
	Jun. 30, 2019USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of liability-classified warrants issued with common stock	$ 7,283
Change in fair value of warrant liability	(2,938)
Ending balance	$ 4,345

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
License Agreement [Line Items]
Remaining insurance note payable	$ 195,344	$ 597,339
Insurance Note Payable [Member]
License Agreement [Line Items]
Principal amount		600,000
Remaining insurance note payable	$ 200,000	$ 600,000
Maturity period	March 18, 2020

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue | shares	8,000,000
Available for offering		$ 17,900,000	$ 17,900,000
Exercise price | $ / shares	$ 2
Warrants issued for common stock dividends	1
Change in fair value of warrant liability		$ 2,938,242
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Number of shares that can be purchased with warrants | shares	8,000,000
ATM Financing Facility [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue | shares		0	2,383,884
Gross proceeds from issuance of common stock			$ 5,800,000
Related cost offset the proceeds			$ 200,000
Underwriters Public Offering [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from underwritten registered offering, net of underwriting discounts and commissions	$ 11,300,000	$ 11,300,000
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Exercise price | $ / shares		$ 2.51	$ 3.42
Fair value of warrants	$ 7.3
Warrant [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Common stock purchase warrants outstanding and exercisable | shares		12,391,405	4,469,836
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue | shares		8,000,000
Common stock price per share | $ / shares	$ 1.50

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail) - Warrant [Member]	3 Months Ended
	Jun. 30, 2019$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant Shares of Common Stock, Outstanding at beginning | shares	4,499,603
Warrant Shares of Common Stock, Granted | shares	8,000,000
Warrant Shares of Common Stock, Exercised | shares	(78,431)
Warrant Shares of Common Stock, Outstanding at ending | shares	12,421,172
Weighted Average Exercise Price, Outstanding at beginning | $ / shares	$ 3.42
Weighted Average Exercise Price, Granted | $ / shares	2
Weighted Average Exercise Price, Exercised | $ / shares	3
Weighted Average Exercise Price, Outstanding at ending | $ / shares	$ 2.51

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2019	Apr. 30, 2019
Class Of Warrant Or Right [Line Items]
Exercise Price		$ 2
Class Of Warrant Or Right Issued on December 2015 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2015-12
Classification	Equity
Warrants Outstanding	446,500
Exercise Price	$ 5
Expiration	2025-12
Class Of Warrant Or Right Issued on February 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-02
Classification	Equity
Warrants Outstanding	491,151
Exercise Price	$ 5
Expiration	2026-02
Class Of Warrant Or Right Issued on March 2017 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2017-03
Classification	Equity
Warrants Outstanding	3,245,288
Exercise Price	$ 3
Expiration	2019-09
Class Of Warrant Or Right Issued on April 2017 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2017-04
Classification	Equity
Warrants Outstanding	238,233
Exercise Price	$ 3
Expiration	2019-09
Class Of Warrant Or Right Issued on April 2019 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2019-04
Classification	Liability
Warrants Outstanding	8,000,000
Exercise Price	$ 2
Expiration	2024-04

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant Liability (Detail) - Warrant [Member]	Jun. 30, 2019	Apr. 02, 2019
Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0122	0.0185
Volatility [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.56	0.48
Remaining Term [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	4 years 9 months 3 days	5 years
Risk-free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0175	0.0228

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) - USD ($)	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Commitment And Contingencies [Line Items]
Research study estimated cost		$ 2,720,762	$ 3,010,688
Contractual obligation	$ 2,500,000	$ 2,500,000
Clinical Research Funding and Drug Supply Agreement [Member] | Pancreatic Cancer Action Network [Member]
Commitment And Contingencies [Line Items]
Research study estimated cost	$ 7,000,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Leases [Line Items]
Rent expense	$ 76,000	$ 43,000
Incremental borrowing rate to calculate present value of lease payments	6.00%
New Jersey [Member] | Office Space [Member]
Leases [Line Items]
Operating lease, expiration term	2021-02

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements (Detail) - USD ($)	Jun. 30, 2019	Apr. 01, 2019
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2020	$ 44,000
2021	58,000
Total remaining lease payments	102,000
Less: present value adjustment	(5,000)
Total operating lease liabilities	97,000	$ 103,994
Less: current portion	(55,141)
Operating lease liabilities, net of current portion	$ 42,001

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Drinker, Biddle & Reath LLP ("DBR") [Member] - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Related Party Transaction [Line Items]
Legal fees	$ 152,000	$ 400,000
Accounts payable and accrued expenses payable	$ 377,000		$ 325,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Unrecognized compensation expense	$ 8,300,000
Unrecognized compensation expense recognition period	1 year 1 month 2 days
Number of shares available for grants | shares	5,181,012
Equity Incentive Plan 2015 and 2016 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Aggregate intrinsic value, options	$ 0
Share price (in dollars per share) | $ / shares	$ 1.22

Equity Incentive Plan - Allocat

Equity Incentive Plan - Allocation of Share Based Compensation (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 1,625,000	$ 2,338,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	955,000	1,661,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 670,000	$ 677,000

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Used to Estimate the Fair Value of Stock Options Granted (Detail)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Summary Of Stock Option Activities [Line Items]
Risk free interest rate		2.87%
Expected volatility		75.09%
Expected term (in years)		5 years 10 months 28 days
Dividend yield	0.00%	0.00%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	1.91%
Expected volatility	71.65%
Expected term (in years)	2 years 6 months
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	2.38%
Expected volatility	76.22%
Expected term (in years)	6 years

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	3 Months Ended
	Jun. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	8,953,527
Granted | shares	2,507,280
Outstanding at ending | shares	11,460,807
Options exercisable | shares	6,095,259
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 4.13
Granted | $ / shares	1.55
Outstanding at ending | $ / shares	3.57
Options exercisable | $ / shares	$ 4.65

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - Exercise Price $1.04 - $8.75 [Member]	3 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Stock Options Outstanding
Range of Exercise Price, Lower Limit	$ 1.04
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding | shares	11,460,807
Weighted Average Exercise Price	$ 3.57
Weighted Average Remaining Life (Years)	8 years 1 month 9 days
Aggregate Intrinsic Value | $	$ 0
Stock Options Vested
Stock Options Vested | shares	6,095,259
Weighted Average Exercise Price	$ 4.65
Aggregate Intrinsic Value | $	$ 0